학술논문
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial
Document Type
Article
Author
Source
In The Lancet Infectious Diseases March 2024 24(3):308-318
Subject
Language
ISSN
1473-3099